Formulation of apomorphine for the treatment of Parkinson
Apomorphine, as a powerful dopaminergic receptor agonist, is an effective drug used in the treatment of Parkinson's disease in patients who have become poorly responsive to treatment or have developed negative side effects associated with chronic levodopa treatment. However, due to its high instability, limited pharmacokinetics, low bioavailability and rapid clearance from plasma its effect in patients is limited to 30-40 minutes. The pharmaceutical formulation according to the invention allows to stabilize apomorphine and to improve its bioavailability avoiding its degradation, allows to maintain an adequate concentration of the drug in the blood even after 24 hours from oral administration and is therefore able to improve the therapeutic treatment of Parkinson's disease.
- Treatment of patients with Parkinson's disease poorly responsive to treatment with levodopa
- Reduction of “off” conditions that may occur in Parkinsonian patients
- Treatment of Parkinson’s disease in addition to standard therapy, in order to reduce levodopa dosages and the consequences related to the chronic levodopa syndrome
- Stabilization of apomorphine
- Use of nano-vectors free of any form of toxicity
- Prolonged release of the active ingredient
- Oral administration of apomorphine
- Trotta Francesco
- Mauro Alessandro
- Cavalli Roberta
- Priano Lorenzo
- Cattaldo Stefania
Filing date: 19/04/2021
Application number: 102021000009857
Yes
- Università degli Studi di Torino 60%
- Istituto Auxologico Italiano 40%